Making cancer fight itself: The promise of PROTACs
Proteolysis-targeting chimeras, or PROTACs, are a new area of research in medicinal chemistry; they can leverage cancer cells’ own protein degradation machinery to target cancerous proteins.

Jianchao Zhang, a research assistant professor at Southern University of Science and Technology, or SUSTech, has always been interested in the mechanism underlying cancer development, and he became intrigued by PROTACs after learning of their potential while working in Hai Rao’s lab. Zhang and his colleagues recently discovered a PROTAC with the potential to treat chronic myeloid leukemia, a type of blood cancer.
“PROTACs are one of the most promising technologies in the biomedical field today and offer significant advantages in overcoming drug resistance and targeting undruggable targets due to their unique design and mechanism of action,” Zhang said.
In the beginning, Zhang worked primarily on cancer biology and metastasis. In 2020, Rao moved from San Antonio, Texas, to SUSTech in Shenzhen, China, where Zhang joined his lab. Zhang and colleagues began searching for chemists to collaborate with to synthesize their PROTACs. A year later, they found Lijing Fang from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, whose expertise in synthetic chemistry enabled them to embark on their PROTAC project in 2022.
Zhang’s journey with PROTACs was not straightforward. His team tried to target other cancerous proteins for PROTAC development, including one involved in lung cancer but encountered many obstacles.
“PROTACs are easy to design but hard to predict the outcome,” Zhang said.
After altering their design approach, they successfully developed their PROTAC, Arg-PEG1-Dasa, which can degrade the cancerous protein BCR-ABL in chronic myeloid leukemia. For the paper in the Journal of Biological Chemistry describing this work, Zhang received a JBC/ Herb Tabor Award.
What’s next for Zhang’s lab? Optimizing chemical structure and protein degradation is a critical part of drug discovery.
“We are interested in exploring the effects on (protein) degradation efficiency and rate by other amino acids,” he said. “Additionally, linker optimization is crucial for PROTACs, and we aim to modify linker types to further enhance this single amino acid PROTAC.”
Zhang and his colleagues are also working on designing PROTACs to target different types of cancer and making their PROTACs smaller to improve cellular uptake.
No FDA-approved PROTACs are yet on the market; however, several have made it to clinical trials.
“Currently, among the known drug targets, only about 20% possess active sites that can be bound by traditional small molecule inhibitors,” Zhang said. “The remaining 80% are considered undruggable or difficult to target with conventional approaches. There is a significant potential that the 80% of undruggable targets could be addressed using PROTAC technology.”
If at first you don’t succeed …
Proteolysis-targeting chimeras, or PROTACs are bifunctional molecules consisting of three structural components: a chemical entity binding to a target protein involved in cancer development (commonly referred to as a “warhead”), a chemical entity that binds to an E3 ligase (protein degrader) and a linker that connects these molecules. Together, these components help degrade cancer-promoting proteins through proximity-induced proteolysis.
PROTACs don’t need to bind to an active site or have high binding affinity to target proteins. This allows for significant flexibility in drug development.
Jianchao Zhang’s PROTAC employs the N-end rule degradation pathway, which determines that a protein’s rate of degradation depends on the identity of the N-terminal amino acid. A family of E3 ubiquitin ligases recognizes basic and hydrophobic amino acids, making them an ideal tag for PROTACs.
Using this rule, Zhang added the amino acid arginine to the FDA-approved chronic myeloid leukemia drug dasatinib with a polyethylene glycol linker. This combination degraded the cancerous protein BCR-ABL in both cells and mice.
Zhang said he was somewhat surprised when his team first observed their PROTAC-inhibiting tumor growth in a mouse model.
“It was not a given that our amino acid–based PROTAC would work,” he said. “In fact, my first set of PROTACs did not work.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

How undergrad research catalyzes scientific careers
Undergraduate research doesn’t just teach lab skills, it transforms scientists. For Antonio Rivera and Julissa Cruz–Bautista, joining a lab became a turning point, fostering critical thinking, persistence and research identity.

Simcox and Gisriel receive mentoring award
They were honored for contributing their time, knowledge, energy and enthusiasm to mentoring postdocs in their labs.

ASBMB names 2025 Marion B. Sewer scholarship recipients
Ten undergraduates interested in biochemistry and molecular biology will each receive $2,000 toward their tuition and related educational costs.

Attie named honorary professor
This award includes $100,000 of research funding and recognizes faculty who have made major contributions to the advancement of knowledge through their research, teaching and service activities.

Meet the 2025 SOC grant awardees
Five science outreach and communication projects received up to $1,000 from ASBMB to promote the understanding of molecular life science.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.